Group One Trading
CMPX icon

Group One Trading’s Compass Therapeutics CMPX Stock Holding History

Group One Trading’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$179K Buy
81,557
+51,328
+170% +$152K ﹤0.01% 4377
2026
Q1 		$160K Buy
30,229
+24,985
+476% +$144K ﹤0.01% 4307
2025
Q4 		$28.2K Buy
+5,244
New +$24.2K ﹤0.01% 6079

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Group One Trading's CMPX Position: Q2 2026 in Review

Group One Trading increased its Compass Therapeutics (CMPX) stake by 170% in Q2 2026, buying an estimated $152K and bringing the position to 81,557 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #4377.

Group One Trading first reported a position in CMPX in Q4 2025 and has held it in 3 quarters since. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Group One Trading held 81,557 shares of Compass Therapeutics worth $179K as of Q2 2026.
  • Group One Trading bought 51,328 Compass Therapeutics shares in Q2 2026, an estimated $152K.
  • Compass Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #4377 holding.
  • Group One Trading first reported a position in Compass Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.